Russia experiencing growing demand for semaglutide-based drugs
The Russian Ministry of Health has registered the third Russian generic of the original drug Ozempic (semaglutide) from Danish drugmaker Novo Nordisk (NOV: N).
Ozempic is intended for patients with type 2 diabetes is planned to be produced by the pharmaceutical company PSK Pharma under the brand name Insudive, reports The Pharma Letter’s local correspondent. Semaglutide is also the active ingredient of Novo Nordisk’s much in demand obesity drug Wegovy.
In December 2023, the Russian drugmakers Geropharm and Promomed received a compulsory license to produce semaglutide under the brands Semavic and Queensenta respectively, and produce it without the consent of the patent owner. In the fall of 2022, Novo Nordisk notified the Russian drug regulator Roszdravnadzor that it would stop supplying Ozempic to Russia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze